Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018 - ResearchByMarkets.com
This report provides an overview of the pipeline landscape for pancreatic and bile duct cancer. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pancreatic and bile duct cancer, and features dormant and discontinued products.
Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas, a large gland situated in the abdominal cavity that is responsible for the secretion of digestive fluids and insulin. Signs and symptoms include upper abdominal pain, yellowing of the skin and the whites of the eyes (jaundice), loss of appetite, weight loss, depression and blood clots.
Predisposing factors include age, gender, smoking, diabetes and family history. Treatments include surgery, chemotherapy and radiation therapy. There are 759 products in development for this indication.
Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile ducts, a series of tubes in the biliary tract that are essential for the secretion of bile, which plays an important role in digestion. Symptoms include discomfort in the abdomen, loss of appetite, fevers and weight loss. Treatment includes chemotherapy and radiation therapy. There are 133 products in development for this indication.
Molecular targets acted on by products in development for pancreatic and bile duct cancer include vascular endothelial growth factor receptors, programmed cell death protein 1 and signal transducer and activator of transcription 3. Companies operating in this pipeline space include Novartis, Eli Lilly and AstraZeneca.
- Which companies are the most active within the pipeline for pancreatic and bile duct cancer?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
Get in touch with us:
Ritesh Tiwari, Director
"Research By Markets" is a Market Research Reports Depository. Our Latest Market Research Reports cover a lot of Industry Sectors - Aerospace and Defense, Automotive and Transportation, Chemicals and Materials, Consumer Goods and Services, Energy and Power, Environmental, Food and Beverages, Healthcare, Information Technology, Manufacturing and Construction, Medical Devices, Petroleum, Pharmaceuticals, Semiconductor and Electronics, Telecommunications and more.
We are trusted by Fortune 500 companies for our client centric support. We have helped our clients in procuring research studies as per their requirements and also ensured they get proper post purchase support. We ensure that all our client queries are addressed in quick time.
We strive our best to ensure that our clients have a seamless experience and are happy and smiling every time they do business with us.
Research By Markets
E/3, Ganga Homes,
Behind Bank Of India,
Pune 411 014.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018 - ResearchByMarkets.com here
News-ID: 1225182 • Views: 244
More Releases from Research By Markets
V2X (Vehicle-to-Everything) Communications Ecosystem expected to grow at a CAGR …
Commonly referred to as V2X, vehicle-to-everything communications technology allows vehicles to directly communicate with each other, roadside infrastructure, and other road users to deliver an array of benefits in the form of road safety, traffic efficiency, smart mobility, environmental sustainability, and driver convenience. In addition, V2X is also helping pave the way for fully autonomous driving through its unique non line-of-sight sensing capability which allows vehicles to detect potential hazards,
Research By Markets - Trusted By Market Leaders
Research By Markets is a Market Research Reports Online Repository. We have a huge database of syndicated market research reports that are segmented by Industry Verticals mainly - Telecommunication, Semiconductor, Electronics, Information Technology, Automotive, Healthcare, Pharmaceutical, Medical Devices, Biotechnology, Energy, Power, Aerospace, Defense, Consumer Goods, Construction, Equipment and many more. Our clientele includes Fortune listed companies who trust us to help them with their market intelligence requirements. Research By Markets being a
Global Veterinary Services Market: Size, Trends and Forecasts (2018-2022) - Rese …
The report titled "Global Veterinary Services Market: Size, Trends and Forecasts (2018-2022)", provides an in depth analysis of the global veterinary services market by value, by segments, by services, by region, etc. The report also provides a regional analysis of the veterinary services market, including the following regions: North America, Europe, Asia Pacific, Latin America and MEA. The report also assesses the key opportunities in the market and outlines the factors
Blood Pressure Disorders Drug Development Pipeline Review, 2018 - ResearchByMark …
"Blood Pressure Disorders Drug Development Pipeline Review, 2018" Summary This report provides an overview of the pipeline landscape for blood pressure disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hypertension, pulmonary arterial hypertension (PAH) and hypotension, and features dormant and discontinued products. Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many
More Releases for Pancreatic
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease. Download the sample report at: https://www.pharmaproff.com/request-sample/1024 Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI
Pancreatic Cancer Pipeline Review H1 2019
Pancreatic Cancer - Pipeline Review, H1 2017 Summary Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and
Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Opportunity Analysis …
Exocrine pancreatic insufficiency (EPI) is a condition associated with deficiency of exocrine pancreatic enzymes that results in the inability to digest food or maldigestion. EPI may be associated with certain diseases and conditions that affect the pancreas such as cystic fibrosis, chronic pancreatitis, Shwachman–Diamond syndrome, and others. Chronic pancreatitis (CP) is the most common cause of EPI in adults that is followed by cystic fibrosis (CF). CF is an inherited
Pancreatic Cancer Pipeline Drugs Review H1 2017
Pancreatic Cancer Pipeline Review H1 2017 provides an overview of the Pancreatic Cancer (Oncology) therapeutics pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. Report provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide
Pancreatic Cancer Drug Pipeline Analysis
“Pancreatic Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each
Exocrine Pancreatic Insufficiency Market 2013
Transparency Market Research has published a new market report titled, “Exocrine Pancreatic Insufficiency Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2023.” According to the report, the exocrine pancreatic insufficiency market is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$2.85 Bn by 2023. Browse the full Exocrine Pancreatic Insufficiency Market – (Therapeutic – Pancreatic Enzyme Replacement Therapy (Creon, Zenpep,